JMP reiterates Oscient at market outperform

Oscient Pharmaceuticals Corp. was reiterated at market outperform by JMP Securities analyst Adam Cutler based on the analyst's weekly tracking of Factive and Testim prescription volumes using NDC Health data. For the week ended April 21, NDC reported that Factive total prescriptions were 5,466 (5,279 new), or 0.87% of weekly prescriptions for the quinolone class of antibiotics, compared with 5,011 total prescriptions (4,821 new) the previous week. Total Testim scripts for the week ended April 21 were 5,205, compared with 5,611 for the previous week. Shares of the Waltham, Mass., biopharmaceutical company were down 3 cents, or 1.69%, at $1.79 on volume of 185,895 shares versus the three-month running average of 429,644 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.